ABL1 and myelofibrosis: In adults PMF and post-ET/PV myelofibrosis (post-ET/PV MF) are BCR::ABL1-neg MPNs with the worst survival rates, but allo-HCT can cure a substantial number of patients, especially those younger than 70 years and with a median survival expectation of less than 5 years [10].